Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01309603 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The coronavirus nsp14 exoribonuclease interface with the cofactor nsp10 is essential for efficient virus replication and enzymatic activity.
J Virol
January 2025
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Coronaviruses (CoVs) encode non-structural proteins (nsp's) 1-16, which assemble to form replication-transcription complexes that function in viral RNA synthesis. All CoVs encode a proofreading 3'-5' exoribonuclease in non-structural protein 14 (nsp14-ExoN) that mediates proofreading and high-fidelity replication and is critical for other roles in replication and pathogenesis. The enzymatic activity of nsp14-ExoN is enhanced in the presence of the cofactor nsp10.
View Article and Find Full Text PDFMedicaid Policy and Hepatitis C Treatment Among Rural People Who Use Drugs.
Med Care
February 2025
Department of Medicine, Section of Infectious Diseases & Global Health, University of Chicago, Chicago, IL.
Background: Restrictive Medicaid policies regarding hepatitis C virus (HCV) treatment may exacerbate rural health care disparities for people who use drugs (PWUD). We assessed associations between Medicaid restrictions and HCV treatment among rural PWUD.
Methods: We compiled state-specific Medicaid treatment policies across 8 US rural sites in 10 states and merged these with participant survey data.
Understanding Barriers to Hepatitis C Antiviral Treatment in Low-Middle-Income Countries.
Healthcare (Basel)
December 2024
Center for Global Emergency Care, Johns Hopkins University, Baltimore, MD 21209, USA.
: Direct-acting antiviral agents (DAAs) have significantly reduced Hepatitis C Virus (HCV) transmission and improved health outcomes since their FDA approval in 2011. Despite these advances, over 70 million people remain untreated globally, with a disproportionately high burden in low- and middle-income countries (LMICs). : Through a structured search of open access informational sources and an informal peer-reviewed literature review, HCV treatment barriers were identified, compiled, and analyzed.
View Article and Find Full Text PDFHepatitis B Virus Knowledge and HBV-Related Surveillance Status Among HBsAg-Positive Patients in Qidong City: A Rural-Based Cross-Sectional Survey.
Healthcare (Basel)
December 2024
School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Objective: This study aimed to investigate hepatitis B knowledge and hepatitis B virus (HBV)-related surveillance status among HBsAg-positive patients, as well as to further explore the relevant influencing factors.
Methods: A cross-sectional study was conducted on the HBsAg-positive patients from 8 October 2023 to 10 November 2023 in Qidong City. A self-report questionnaire was developed based on a literature review of similar studies.
Tenofovir vs. Entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma patients after liver resection: the role of HBsAg levels.
Clin Transl Gastroenterol
January 2025
Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Background: Our study aimed to explore whether hepatitis B surface antigen (HBsAg) levels affected the role of nucleot(s)ide analog treatment (entecavir (ETV) and tenofovir (TDF)) in improving the prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients after liver resection.
Methods: A total of 865 HBV-related HCC patients after hepatectomy treated with TDF or ETV were included in our study. Patients were divided into the high HBsAg cohort (n=681) and the low HBsAg cohort (n=184).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!